Patent US5755226A successfully refreshed from Google Patents.
US5755226A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and apparatus for noninvasive prediction of hematocrit
Assignee: Terumo Cardiovascular Systems Corp
•
Filing: 1996-09-10
•
Granted: 1998-05-26
•
Expires: 2016-09-10
Abstract
Abstract A method and apparatus for the direct noninvasive prediction of hematocrit in mammalian blood using photoplethysmography techniques and data processing. The method and apparatus also include optional prediction of other analytes of interest: percent oxygen saturation of mammalian blood and methemoglobin of stored blood. The method and apparatus can be used for the immediate, periodic, or continuous noninvasive diagnosis or monitoring of hematocrit levels in mammalian patients without pain to the patient or exposure of the health care practitioner to the blood of the patient.
Inventors
- 👤 Hatim M. Carim
- 👤 Orlin B. Knudson
- 👤 Bruce P. Ekholm
- 👤 David P. Erickson
- 👤 William J. Kelliher, Jr.
- 👤 Michael J. Rude
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 22:18
CPC Classifications
A; A61; A61B; A61B5/00; A61B5/145; A61B5/1455; A61B5/14551; A61B5/14552; A61B5/14535; A61B5/68; A61B5/6801; A61B5/6843; A61B5/72; A61B5/7228; G; G01; G01N; G01N21/00; G01N21/17; G01N21/25; G01N21/31; G01N21/314; G01N21/35; G01N21/359; A61B2562/00; A61B2562/02; A61B2562/0233; A61B2562/04; A61B2562/046; A61B5/7235; A61B5/7239; Y; Y10; Y10S; Y10S977/00; Y10S977/902; Y10S977/904; Y10S977/905
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
314 words
An apparatus for the noninvasive prediction of hematocrit within mammalian tissue, comprising: (a) a light source adapted to noninvasively interrogate the mammalian tissue with light of at least two wavelengths, wherein the at least two wavelengths are selected according to wavelength selection criteria, and wherein the wavelength selection criteria comprise: (1) a wavelength where absorbance of water is at or near a measurable peak; (2) at least one wavelength where absorbance of oxyhemoglobin and deoxyhemoglobin are predictable and represent total hemoglobin content; (3) a wavelength where the absorbance of water greatly exceeds the absorbance of all forms of hemoglobin; and (4) a wavelength where the absorbance of all forms of hemoglobin greatly exceeds the absorbance of water; wherein each of the wavelength selection criteria must be satisfied, wherein each selected wavelength can satisfy one or more than one of the wavelength selection criteria, and wherein at least one of the selected wavelengths is in the range 1150-2100 nm; (b) at least one detector adapted to receive light of the selected wavelengths transmitted through the mammalian tissue, the detector further adapted to convert the transmitted light of each selected wavelength from optical signals into electrical signals; and (c) processing means, connected to receive the electrical signals from the detector, the processing means for: determining the intensity of at least one peak, the intensity of at least one valley, and the intensity of at least one direct current value for the transmitted light of each selected wavelength; determining at least one pseudo-absorption H Value for each selected wavelength, wherein each H Value is based on the intensities of the at least one peak, at least one valley, and the at least one direct current value; and determining a prediction equation for the noninvasive prediction of hematocrit, wherein the prediction equation is based on true hematocrit values and the pseudo-absorption H Values determined for each selected wavelength.
Claim 2
Independent Claim
314 words
An apparatus for the noninvasive prediction of hematocrit within mammalian tissue, comprising: (a) a light source adapted to noninvasively interrogate the mammalian tissue with light of at least two wavelengths, wherein the at least two wavelengths are selected according to wavelength selection criteria, and wherein the wavelength selection criteria comprise: (1) a wavelength where absorbance of water is at or near a measurable peak; (2) at least one wavelength where absorbance of oxyhemoglobin and deoxyhemoglobin are predictable and represent total hemoglobin content; (3) a wavelength where the absorbance of water greatly exceeds the absorbance of all forms of hemoglobin; and (4) a wavelength where the absorbance of all forms of hemoglobin greatly exceeds the absorbance of water; wherein each of the wavelength selection criteria must be satisfied, wherein each selected wavelength can satisfy one or more than one of the wavelength selection criteria, and wherein at least one of the selected wavelengths is in the range 1150-2100 nm; (b) at least one detector adapted to receive light of the selected wavelengths transmitted through the mammalian tissue, the detector further adapted to convert the transmitted light of each selected wavelength from optical signals into electrical signals; and (c) processing means, connected to receive the electrical signals from the detector, the processing means for: determining the intensity of at least one peak, the intensity of at least one valley, and the intensity of at least one direct current value for the transmitted light of each selected wavelength; determining at least one pseudo-absorption H Value for each selected wavelength, wherein each H Value is based on the intensities of the at least one peak, at least one valley, and the at least one direct current value; and determining a prediction equation for the noninvasive prediction of hematocrit, wherein the prediction equation is based on true hematocrit values and the pseudo-absorption H Values determined for each selected wavelength.
Claim 3
Dependent Claim
20 words
The apparatus of claim 1, wherein the processing means is further adapted for noninvasively predicting hematocrit using the prediction equation.
Claim 4
Dependent Claim
22 words
The apparatus of claim 2, further comprising: (a) means for calculating a coefficient of variation of the at least one H Value.
Claim 5
Dependent Claim
16 words
The apparatus according to claim 2, further comprising: (d) means for displaying the prediction of hematocrit.
Claim 6
Dependent Claim
14 words
The apparatus of claim 1, wherein the modulated light source maintains relative spectral intensity.
Claim 7
Dependent Claim
42 words
The apparatus according to claim 1, wherein the wavelength selection criteria further comprises: (5) a wavelength where the absorbance of oxyhemoglobin greatly exceeds the absorbance of deoxyhemoglobin; and (6) a wavelength where the absorbance of deoxyhemoglobin greatly exceeds the absorbance of oxyhemoglobin.
Claim 8
Dependent Claim
72 words
The apparatus according to claim 6, wherein the wavelength selection criteria further comprises: (7) at least one different wavelength from selection criteria (1) where the absorbance of water is at or near a measurable peak or shoulder and is subjected to differing interferences than selection criteria (1); and (8) a wavelength where the absorbance of water is in or near a valley between peaks and where the absorbance of hemoglobin is minimal.
Claim 9
Dependent Claim
25 words
The apparatus according to claim 7, wherein the wavelength selection criteria further comprises: (9) a wavelength where water and hemoglobin are in an isosbestic relationship.
Claim 10
Dependent Claim
111 words
The apparatus according to claim 8, wherein the wavelength selection criteria (1) has a range of about 1160-1230 nm; wherein the wavelength selection criteria (2) has a range of about 800-850 nm; wherein the wavelength selection criteria (3) has a range of about 1150-2100 nm; wherein the wavelength selection criteria (4) has a range of about 450-690 nm; wherein the wavelength selection criteria (5) has a range of about 650-690 nm; wherein the wavelength selection criteria (6) has a range of about 890-920 nm; wherein the wavelength selection criteria (7) has a range of about 960-990 nm; and wherein the wavelength selection criteria (8) has a range of about 1100-1120 nm.
Claim 11
Dependent Claim
20 words
The apparatus according to claim 1, further comprising a fresnel lens to shape the transmitted light of each selected wavelength.
Claim 12
Dependent Claim
25 words
The apparatus according to claim 1, further comprising a high common mode rejection amplifier for amplifying and filtering the transmitted light of each selected wavelength.
References Cited (Backward Citations)
US3923397A
Cited
US4303336A
Cited
US4227814A
Cited
US4562843A
Cited
US4447150A
Cited
US4407290A
Cited
US4407290B1
Cited
US4621643A
Cited
US4653498A
Cited
US4653498B1
Cited
US4548211A
Cited
US4586313A
Cited
US4685464A
Cited
US4936679A
Cited
US4745279A
Cited
US4832484A
Cited
US5193543A
Cited
US4776340A
Cited
US4805623A
Cited
US4819752A
Cited
US4883353A
Cited
US4869254A
Cited
US5078136A
Cited
US5101825A
Cited
US4975581A
Cited
US5200345A
Cited
EP0476192A2
Cited
EP0419223A2
Cited
US5137023A
Cited
US5372136A
Cited
WO1992013482A1
Cited
US5233991A
Cited
US5277181A
Cited
WO1993013706A2
Cited
US5297548A
Cited
US5337745A
Cited
US5355880A
Cited
US5406223A
Cited
US5553613A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-05-25 | 2001-11-24 | 2002-05-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-05-25 | 2005-11-24 | 2006-05-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-05-25 | 2009-11-24 | 2010-05-26 | $7700.00 | Window Closed / Lapsed |